126156-28-3

Upstream product

• 589-18-4 4-Methylbenzyl alcohol 
• 126156-20-5 (2-iodo-4-methylphenyl)methanol 
• 81335-87-7 (2-amino-4-methylphenyl)methanol 
• 2305-36-4 4-methylanthranilic acid 
• 50-00-0 formaldehyd 
• 29289-13-2 2-iodo-4-methylaniline 

Downstream Products

• 1829-21-6 4-methyl-2-iodobenzoic acid 
• 1192931-07-9 N-(2-iodo-4-methylbenzylidene)-4-methoxyaniline 
• 1192930-97-4 N-(2-iodo-4-methylbenzylidene)-2-methylpropan-2-amine 
• 1206626-35-8 ethyl 2-azido-3-(2-iodo-4-methylphenyl)acrylate 
• 1241405-38-8 methyl 1-[3-iodo-4-(1-methoxy-1-oxopropan-2-yl)-benzyl]-2-oxocyclopentanecarboxylate 
• 1313592-03-8 sodium 2-{2-iodo-4-[(2-oxocyclopentyl)methyl]phenyl}propanoate 
• 1241405-25-3 C₉H₉IO 
• 1241405-34-4 C₁₁H₁₂BrIO₂ 
• 1241405-30-0 methyl 2-(2-iodo-4-methylphenyl)propanoate 
• 90585-28-7 2-(2-iodo-4-methylphenyl)acetic acid 
• 90585-27-6 methyl 2-iodo-4-methylphenylacetate 
• 1300635-93-1 6-methyl-3,4-diphenylisoquinoline 
• 1382240-16-5 C₂₁H₂₁NO₃S 
• 1382240-44-9 N-allyl-N-(3-(2-(hydroxy(phenyl)methyl)-5-methylphenyl)prop-2-yn-1-yl)-4-methylbenzenesulfonamide 

Relevant academic research and scientific papers

Cu-Catalyzed Enantioselective Ring Opening of Cyclic Diaryliodoniums toward the Synthesis of Chiral Diarylmethanes

A Cu-catalyzed enantioselective desymmetrizing ring-opening reaction of six-membered cyclic diaryliodonium salts with carboxylic acids or thioacids is reported for the facile access to chiral diarylmethanes. A Cu/[cyclopropyl bis(oxazoline)] catalyst well

LOXOPROFEN DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME

There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and

Synthesis and biological evaluation of loxoprofen derivatives

Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.

Synthesis of 4-Alkyl-2-iodosobenzoic Acids: Potent Catalysts for the Hydrolysis of Phosphorous Esters

The syntheses of five new 4-alkyl-2-iodosobenzoic acids (3) are described.The iodine atom was introduced by ortho-directed lithiation of 4-alkylbenzyl alcohols followed by treatment with I2.The catalytic effectiveness of each of the products in the hydrolysis of 4-nitrophenyl diphenyl phosphate in microemulsions was studied.The 4-methyl- and 4-ethyl-substituted products were each found to be significantly better catalysts than the standard nonalkylated 2-iodosobenzoic acid (3, R=H).These results would indicate that microemulsions of these materials may find use in detoxification procedures.